Extracellular glypican‐1 affects tumor progression and prognosis in esophageal cancer
These results demonstrated the utility of extracellular GPC1 as a biomarker, which can be assayed from a less invasive blood sample-based liquid biopsy. Extracellular GPC1 protein plays a role in both tumor cell motility and cancer progression. Thus, plasma GPC1 is a useful biomarker for esophageal cancer progression and may be a potential candidate of therapeutic target.
Authors
- Takeshi Kubota
- Shuhei Komatsu (ORCID: https://orcid.org/0000-0001-6074-7614)
- Atsushi Shiozaki (ORCID: https://orcid.org/0000-0003-3739-160X)
- Hirotaka Konishi (ORCID: https://orcid.org/0000-0002-4899-8944)
- Hitoshi Fujiwara (ORCID: https://orcid.org/0000-0002-6507-4313)
- Rie Shibata (ORCID: https://orcid.org/0009-0004-9462-5964)
- H. Shimizu (ORCID: https://orcid.org/0000-0002-6599-5358)
- Eigo Otsuji (ORCID: https://orcid.org/0000-0002-3260-8155)
- Takuma Ohashi
- Tomohiro Arita (ORCID: https://orcid.org/0000-0001-7127-6504)
- Hayato Matsuda
- Yusuke Yamamoto
- T. Yamamoto
Institutions
- Kyoto Prefectural University of Medicine (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/cam4.70212
- Primary Topic
- Proteoglycans and glycosaminoglycans research
- Type
- article
- Field-Weighted Citation Impact
- 0.00